What is the clinical evidence from this study?

Study design: RCT. Population: Hypertension (n=449). Intervention: Dilevalol vs. Metoprolol (100 to 400 mg). Primary outcome: Treatment discontinuation (p=<0.03).

What does this research mean for the field?

Dilevalol effectively reduces blood pressure comparable to metoprolol while resulting in significantly lower overall discontinuation rates and fewer withdrawals from depression and impotence. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 1, 1989The American Journal of CardiologyOpen Access

Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: Results of a multicenter comparison of dilevalol and metoprolol

Q: What are the key findings of this study?

Dilevalol effectively reduced blood pressure with a lower overall discontinuation rate than metoprolol (9% vs 16%, p<0.03) and fewer withdrawals due to depression or impotence.

Q: What does this research mean for the field?

Dilevalol effectively reduces blood pressure comparable to metoprolol while resulting in significantly lower overall discontinuation rates and fewer withdrawals from depression and impotence. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Dilevalol cuts treatment discontinuations ~44% versus metoprolol, with fewer depression- and impotence-related withdrawals.

P<0.03
n=449

Why the study?

The influence of beta2 agonism combined with beta1 and beta2 antagonism on adverse effects and plasma lipoproteins compared to beta1 selective antagonism was unclear.

Population

311 patients randomized to dilevalol and 138 to metoprolol in a multicenter trial

Comparison

Dilevalol (beta2 agonism and nonselective beta antagonism) vs metoprolol (beta1 selective antagonist)

Design

Multicenter randomized trial

Follow-up

1 year

Authors

BMBarry J. MatersonPreventive Cardiology NVN. D. VlachakisUniversity of Southern California SGStephen P. GlasserPreventive Cardiology

Discussion

Member takes

Implication

Dilevalol matches metoprolol for BP control with fewer discontinuations and favorable lipid shifts; extends evidence for beta2 agonism benefits in hypertension.

Study Design

Type

RCT (n=449)

Multicenter

Yes

PICO

Population

449 patients (mean age 51, 28% female) with hypertension requiring blood pressure reduction, followed for 1 year.

Intervention / Comparator

Dilevalol vs Metoprolol (100 to 400 mg) (200 to 1,600 mg once daily)

Primary Outcome

Treatment discontinuation, p=<0.03

Main Result

Absolute Event Rate: 9% vs 16%

p-value: p=<0.03

Cite This Study

Materson et al. (1989) conducted an RCT in Hypertension (n=449). Dilevalol vs. Metoprolol (100 to 400 mg) was evaluated on Treatment discontinuation (p=<0.03). Dilevalol effectively reduced blood pressure with a lower overall discontinuation rate than metoprolol (9% vs 16%, p<0.03) and fewer withdrawals due to depression or impotence.

synapsesocial.com/papers/6ac5adcb0c91f3d71d3e2695 https://doi.org/10.1016/0002-9149(89)90131-8

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Dilevalol matches metoprolol for BP control with fewer discontinuations and favorable lipid shifts; extends evidence for beta2 agonism benefits in hypertension.

Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: Results of a multicenter comparison of dilevalol and metoprolol

Discussion

Member takes

Implication

Study Design

PICO

Main Result

Cite This Study

Topics

Influence of beta2 agonism and beta1 and beta2 antagonism on adverse effects and plasma lipoproteins: Results of a multicenter comparison of dilevalol and metoprolol

Discussion

Member takes

Implication

Study Design

PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider